<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494179</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00102</org_study_id>
    <nct_id>NCT03494179</nct_id>
  </id_info>
  <brief_title>A Study to Investigate ICP-022 in Chinese Patients With R/R Mantle Cell Lymphoma (MCL)</brief_title>
  <official_title>A Phase I/II Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics/ Pharmacodynamics of ICP-022 in Chinese Patients With Relapsed/Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phase I/II clinical study is to investigate the safety, tolerability and
      pharmacokinetics/ pharmacodynamics of ICP-022.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part I: PK/PD and safety evaluation -Two regimens of ICP-022 (High dose QD and low dose BID)
      were designed for assessment of safety, as well as PK/PD profiles. The recommended dose of
      phase II clinical study will be determined according to the Part I results.

      Part II: Dose expansion -Anti-tumor effects of ICP-022 in Chinese patients with R/R MCL will
      be evaluated in approximately 80 subjects. The recommended Phase 2 dose will be used in the
      Part II.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The efficacy measured by overall response rate (ORR) in Part II according to the 2014 International Working Group NHL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response rate (CRR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The efficacy measured by complete response rate (CRR) in Part II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression (TTP)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The efficacy measured by time to progression (TTP) in Part II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The efficacy measured by progression free survival (PFS) in Part II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The efficacy measured by duration of response (DOR) in Part II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The efficacy measured by overall survival (OS) in Part II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve up to the time &quot;t&quot; (AUC(0-t))</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Area under the concentration time curve up to the time &quot;t&quot; (AUC(0-t)) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of target occupancy</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>PBMC from individual subject before and after dosing will be collected and the target occupancy will be determined by ELISA. The percent of target occupancy will be compared descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma drug concentrations (Cmax)</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Individual plasma concentrations of ICP-022 will be measured and Cmax will be calculated with noncompartmental analysis using WinNonlin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma drug concentrations (Tmax)</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Time of maximum plasma drug concentrations (Tmax) of ICP-022 will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent half-life for designated elimination phases (t½)</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Apparent half-life for designated elimination phases (t½) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve up to the last data point above LOQ (AUC(last))</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Area under the concentration time curve up to the last data point above LOQ (AUC(last)) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>High Dose of ICP-022</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose of ICP-022</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICP-022</intervention_name>
    <description>The drug product is a white, round, uncoated tablet.</description>
    <arm_group_label>High Dose of ICP-022</arm_group_label>
    <arm_group_label>Low Dose of ICP-022</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between 18 and 75 years old

          -  Histologically confirmed mantle cell lymphoma (MCL), with either t(11;14) by
             cytogenetics and/or cyclin D1 overexpression by immunohistochemistry (IHC)

          -  Subjects with refractory or relapsed mantle cell lymphoma who has received at least 1
             but no more than 5 prior therapies for MCL

          -  At least one measurable tumor of greater than 1.5 centimeter in long axis by
             contrast-enhanced CT/MRI

          -  ECOG performance status of 0-2

          -  Documented failure to achieve at least partial response (PR) or documented disease
             progression after response to, the most recent treatment regimen.

          -  Subjects who meet the following laboratory parameters:

               1. Absolute neutrophil count (ANC) ≥ 1.5×109/L Platelet count ≥ 75×109/L,
                  independent of growth factor support within 7 days of the first dose with study
                  drug, Hemoglobin ≥ 80 g/L; ANC ≥ 1.0×109/L, Platelet count ≥ 50×109/L if bone
                  marrow involvement

               2. Total bilirubin ≤ 2× ULN; AST or ALT ≤ 2.5 ULN; Creatinine clearance ≥ 30ml/min;
                  Amylase ≤ ULN and Lipase ≤ ULN

               3. International normalized ratio (INR) ≤ 1.5 ULN and activated partial
                  thromboplastin time (APTT) ≤ 1.5 ULN

          -  Life expectancy ≥ 4 months

          -  Able to provide signed written informed consent

        Exclusion Criteria:

          -  History of other active malignancies within 5 years of study entry, unless cured
             without evidence of relapse or metastasis

          -  Current or history of lymphoma involved central nervous system

          -  Prior corticosteroids (at dosages equivalent to prednisone &gt; 20 mg/day) given with
             anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation
             therapy, or antibody based therapies or anti-cancer TCM within 4 weeks of the start of
             study drug.

          -  Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy

          -  Current clinically significant cardiovascular disease including:

               -  Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or
                  myocardial infarction defined by the New York Heart Association Functional
                  Classification, or left ventricular ejection fraction (LVEF) &lt; 50%

               -  Primary cardiomyopathy

               -  Clinical significant QTc prolong history or QTc&gt;470ms (female) QTc&gt;450ms (male)

               -  Uncontrolled hypertension

          -  Known active bleeding within 2 months of screening or currently taking
             anticoagulant/antiplatelet drugs

          -  Urine protein ≥ 2+ and quantitation ≥ 2g/24hours

          -  History of deep vein thrombosis or pulmonary embolism

          -  Disease significantly affecting gastrointestinal function such as dysphagia, chronic
             diarrhea, intestinal obstruction, or resection of the stomach

          -  Allogeneic stem cell transplant within 6 months prior to first dose of study drug or
             related active infection

          -  Major surgery within 6 weeks of screening, except for diagnostic test or vascular
             access setup

          -  Known active infection with HBV, HCV or HIV or any uncontrolled active systemic
             infection

          -  Any history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation
             pneumonitis, drug-related pneumonia, severe lung function impairment

          -  Prior exposure to a BTK inhibitor

          -  Suitable and ready for allogeneic stem cell transplant

          -  Inability to comply with study procedures

          -  Drug abuser or alcoholics

          -  Lactating or pregnant women, or women who will not use contraception during the study
             and for 180 days after the last dose of study drug if sexually active and able to bear
             children

          -  Requires treatment with moderate or strong cytochrome P450 family 3, subfamily A
             (CYP3A) inhibitors or strong CYP3A inducers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuqin Song, MD</last_name>
    <phone>010-88196393</phone>
    <email>songyuqin622@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Province Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaiyang Ding, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongmei Jing, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102206</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JUN ZHU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianda Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiming Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shunqing Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lihong Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zunmin Zhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongping Song, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianfeng Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Cheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sujun Gao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaojing</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaobo Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital and Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoling Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hosptial of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunyan Ji, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongguo Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital Affiated to Shanghai Jiao Tong University School of Medicin</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siguo Hao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ting Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huilai Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengjiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Jin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haiyan Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohong Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kang Yu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

